ALLMedicine™ Granulomatosis With Polyangiitis Center
Research & Reviews 1,300 results
https://clinicaltrials.gov/ct2/show/NCT02257866
Jan 26th, 2023 - The purpose of this protocol is to study the natural history of idiopathic systemic vasculitis in children and adults. The idiopathic vasculitides are a group of rare, systemic diseases involving inflammation of arteries and other tissue with resu...
https://doi.org/10.1159/000529085
Respiration; International Review of Thoracic Diseases; Zhou P, Li Z et. al.
Jan 25th, 2023 - Interstitial lung disease (ILD) is a common pulmonary manifestation of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). We aimed to clarify the clinical predictors of mortality in a cohort of patients with AAV-related ILD (AAV-ILD)...
https://doi.org/10.1177/00045632231154752
Annals of Clinical Biochemistry; Ha JW, Pyo JY et. al.
Jan 19th, 2023 - This study investigated the predictive potential of the albumin-to-alkaline phosphatase ratio (AAPR) for cerebrovascular accident (CVA) occurrence in patients with antineutrophil cytoplasmic antibody-associated vasculitis. This study included 239 ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850589
BMC Ophthalmology; Dammacco R, Biswas J et. al.
Jan 19th, 2023 - Ocular manifestations of granulomatosis with polyangiitis (GPA) have been reported in a limited number of studies and with largely variable frequency. Here we report on the clinical, diagnostic, and therapeutic features of a cohort of 63 GPA patie...
https://doi.org/10.1093/rheumatology/kead015
Rheumatology (Oxford, England); Giaglis S, Daoudlarian D et. al.
Jan 17th, 2023 - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). ANCA triggers neutrophil extracellular trap formation, which releases either mitochondrial ...
Guidelines 4 results
https://doi.org/10.1002/art.41982
Arthritis & Rheumatology (Hoboken, N.J.); Grayson PC, Ponte C et. al.
Feb 3rd, 2022 - To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) iden...
https://doi.org/10.1002/art.41986
Arthritis & Rheumatology (Hoboken, N.J.); Robson JC, Grayson PC et. al.
Feb 3rd, 2022 - To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of ...
https://doi.org/10.1002/art.41773
Arthritis & Rheumatology (Hoboken, N.J.); Chung SA, Langford CA et. al.
Jul 9th, 2021 - To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic...
https://doi.org/10.1016/j.carpath.2015.05.001
Cardiovascular Pathology : the Official Journal of the So... Stone JR, Bruneval P et. al.
Jun 9th, 2015 - Inflammatory diseases of the aorta include routine atherosclerosis, aortitis, periaortitis, and atherosclerosis with excessive inflammatory responses, such as inflammatory atherosclerotic aneurysms. The nomenclature and histologic features of thes...
Drugs 7 results see all →
Clinicaltrials.gov 51 results
https://clinicaltrials.gov/ct2/show/NCT02257866
Jan 26th, 2023 - The purpose of this protocol is to study the natural history of idiopathic systemic vasculitis in children and adults. The idiopathic vasculitides are a group of rare, systemic diseases involving inflammation of arteries and other tissue with resu...
https://clinicaltrials.gov/ct2/show/NCT03164473
Dec 13th, 2022 - Rituximab, an anti-CD20 monoclonal antibody, has been shown to be as effective as cyclophosphamide to induce GPA and MPA remission, with an acceptable safety profile, leading to its registration by the FDA and EMA as remission-induction therapy in...
https://clinicaltrials.gov/ct2/show/NCT05263934
Dec 7th, 2022 - This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
https://clinicaltrials.gov/ct2/show/NCT03298061
Nov 28th, 2022 - Eosinophilic Granulomatosis with Polyangiitis (EGPA), also referred to as Churg-Strauss syndrome, is a rare hyper-eosinophilic syndrome. Eosinophilia is central to the pathophysiology of EGPA and interleukin-5 (IL-5) is a key cytokine regulating t...
https://clinicaltrials.gov/ct2/show/NCT05364892
Oct 31st, 2022 - Vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA) is a group of rare and severe autoimmune diseases, encompassing several entities: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (PMA), and eosinophilic granu...
News 154 results
https://www.medpagetoday.com/rheumatology/generalrheumatology/102772
Jan 24th, 2023 - VEXAS syndrome, a newly discovered inflammatory disease that has rheumatologic and hematologic features caused by mutations in the UBA1 gene, may be as common as Behcet's disease or myelodysplastic syndrome (MDS), researchers reported. In an analy...
https://www.mdedge.com/rheumatology/article/259837/lupus-connective-tissue-diseases/rituximab-raises-remission-rate
Sara Freeman
Nov 30th, 2022 - More patients with granulomatosis with polyangiitis (GPA) were in remission at 6 months if they had received rituximab (Rituxan) rather than cyclophosphamide (Cytoxan) as induction therapy, according to a target trial emulation performed by the Fr.
https://www.medscape.com/viewarticle/984760
Nov 30th, 2022 - More patients with granulomatosis with polyangiitis (GPA) were in remission at 6 months if they had received rituximab (Rituxan) rather than cyclophosphamide (Cytoxan) as induction therapy, according to a target trial emulation performed by the Fr...
https://www.medscape.com/viewarticle/983971
Nov 12th, 2022 - Researchers have found a link between age of diagnosis and various clinical characteristics and outcomes in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The findings, presented Saturday at the American Coll...
https://www.mdedge.com/rheumatology/article/255157/lupus-connective-tissue-diseases/updated-eular-recommendations-aav
Sara Freeman
Jun 2nd, 2022 - The European Alliance of Associations for Rheumatology has updated its recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). The 2022 revision – which was unveiled at the annual European Cong.